In searching for a treatment for frequently fatal severe sepsis, researchers identified recombinant APC, which does not require TM activation, and developed this into the sepsis treatment drotrecogin alfa (activated), marketed as XigrisTM by Eli Lilly. Here, APC is linked to Sepsis.